BioStem made the announcement on November 20, 2024. The company indicated that the acquisition of revyve TM Antimicrobial Wound Gel reflects BioStem’s continued commitment to building a diverse ...

Uneven results in recent years, and in the year to date, have tested the resilience of biotech investors. These companies drive medical innovation, developing therapies that can revolutionize ...

(the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the ...

“We are excited to bring this much needed product to Canada,” said Marc Edwards, President & CEO. “Congratulations to the Kane Biotech team for achieving this important milestone and continue to ...